113 related articles for article (PubMed ID: 15223613)
1. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression.
Merendino RA; Di Pasquale G; De Luca F; Di Pasquale L; Ferlazzo E; Martino G; Palumbo MC; Morabito F; Gangemi S
Mediators Inflamm; 2004 Jun; 13(3):205-7. PubMed ID: 15223613
[TBL] [Abstract][Full Text] [Related]
2. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation.
Echigo T; Hasegawa M; Shimada Y; Takehara K; Sato S
J Allergy Clin Immunol; 2004 May; 113(5):940-8. PubMed ID: 15131578
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of macrophage inflammatory proteins MIP-1alpha and MIP-1beta and interleukin 8 (il-8) in lyme borreliosis.
Grygorczuk S; Pancewicz S; Zajkowska J; Kondrusik M; Rwierzbińska R; Hermanowska-Szpakowicz T
Infection; 2004 Dec; 32(6):350-5. PubMed ID: 15597225
[TBL] [Abstract][Full Text] [Related]
5. Viral macrophage inflammatory protein-II and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1.
Davis CN; Zujovic V; Harrison JK
Mol Pharmacol; 2004 Dec; 66(6):1431-9. PubMed ID: 15361546
[TBL] [Abstract][Full Text] [Related]
6. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
Matsunawa M; Isozaki T; Odai T; Yajima N; Takeuchi HT; Negishi M; Ide H; Adachi M; Kasama T
Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
[TBL] [Abstract][Full Text] [Related]
7. Macrophage inflammatory protein-1alpha: a link between innate immunity and familial Mediterranean fever?
Dizdar O; Kalyoncu U; Karadag O; Akdogan A; Kiraz S; Ertenli I; Barista I; Calguneri M
Cytokine; 2007 Jan; 37(1):92-5. PubMed ID: 17270460
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of chemokines in acute myocardial infarction.
Kobusiak-Prokopowicz M; Orzeszko J; Mazur G; Mysiak A; Orda A; Mazurek W
Kardiol Pol; 2005 Apr; 62(4):301-14; discussion 315-6. PubMed ID: 15928736
[TBL] [Abstract][Full Text] [Related]
9. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.
Inoue A; Hasegawa H; Kohno M; Ito MR; Terada M; Imai T; Yoshie O; Nose M; Fujita S
Arthritis Rheum; 2005 May; 52(5):1522-33. PubMed ID: 15880599
[TBL] [Abstract][Full Text] [Related]
10. The CX3C-chemokine fractalkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea.
Gangemi S; Cannavò SP; Guarneri F; Merendino RA; Sturniolo GC; Minciullo PL; Di Pasquale G; Valenzise M; Drago F; Rebora A
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1366-7. PubMed ID: 17062081
[No Abstract] [Full Text] [Related]
11. [Effects of the chemokine MIP-1alpha on anemia and inflammation in rheumatoid arthritis].
Kullich W; Niksic F; Burmucic K; Pöllmann G; Klein G
Z Rheumatol; 2002 Oct; 61(5):568-76. PubMed ID: 12399885
[TBL] [Abstract][Full Text] [Related]
12. Serum chemokine profile in patients with bullous pemphigoid.
Nakashima H; Fujimoto M; Asashima N; Watanabe R; Kuwano Y; Yazawa N; Maruyama N; Okochi H; Kumanogoh A; Tamaki K
Br J Dermatol; 2007 Mar; 156(3):454-9. PubMed ID: 17300233
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
Bjerkeli V; Damås JK; Fevang B; Holter JC; Aukrust P; Frøland SS
Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
[TBL] [Abstract][Full Text] [Related]
14. [Concentration of macrophage inflammatory proteins MIP-1 alpha and MIP-1 beta and interleukin 8 in erythema migrants].
Grygorczuk SS; Pancewicz S; Kondrusik M; Zajkowska J; Swierzbińska R; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2002 Jun; 12(72):458-61. PubMed ID: 12362660
[TBL] [Abstract][Full Text] [Related]
15. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha and IL-4 regulate expression of fractalkine (CX3CL1) as a membrane-anchored proadhesive protein and soluble chemotactic peptide on human fibroblasts.
Yoshikawa M; Nakajima T; Matsumoto K; Okada N; Tsukidate T; Iida M; Otori N; Haruna S; Moriyama H; Imai T; Saito H
FEBS Lett; 2004 Mar; 561(1-3):105-10. PubMed ID: 15013759
[TBL] [Abstract][Full Text] [Related]
18. The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement.
Morabito F; Merendino RA; Penna G; Cuzzola M; Stelitano C; Callea V; Di Pasquale G; Minciullo PL; Gangemi S
Acta Haematol; 2005; 113(2):152-4. PubMed ID: 15802897
[No Abstract] [Full Text] [Related]
19. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.
Terpos E; Anagnostopoulos A; Kastritis E; Bamias A; Tsionos K; Dimopoulos MA
Br J Haematol; 2006 May; 133(3):301-4. PubMed ID: 16643432
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model.
Pender SL; Chance V; Whiting CV; Buckley M; Edwards M; Pettipher R; MacDonald TT
Gut; 2005 Aug; 54(8):1114-20. PubMed ID: 16009684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
